Management of multidrug-resistant viruses in the immunocompromised host

Br J Haematol. 2012 Mar;156(5):559-72. doi: 10.1111/j.1365-2141.2011.08988.x. Epub 2011 Dec 22.

Abstract

Multidrug-resistant viruses remain a clinically challenging complication in the immunocompromised host. This review discusses mechanisms of viral resistance and treatment options in this context with particular emphasis on the immunocompromised haematology patient. We also outline some of the newer agents and treatment strategies being developed to treat multidrug-resistant viruses.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Cytomegalovirus / drug effects*
  • Cytomegalovirus Infections / drug therapy
  • Cytomegalovirus Infections / immunology
  • Drug Resistance, Multiple, Viral / drug effects*
  • Drug Resistance, Multiple, Viral / immunology
  • Herpes Simplex / drug therapy
  • Herpes Simplex / immunology
  • Herpes Zoster / drug therapy
  • Herpes Zoster / immunology
  • Herpesviridae / drug effects*
  • Herpesvirus 3, Human / drug effects
  • Humans
  • Immunocompromised Host
  • Simplexvirus / drug effects

Substances

  • Antiviral Agents